Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,615 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04409639 | Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations(CONCERTO) | active not recruiting | Phase 2 | 14 | University of UtahOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03190915 | Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia | active not recruiting | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Jul 20, 2026 |
| NCT03739502 | A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant(HBO-UBC) | active not recruiting | Phase 2 | 64 | University of RochesterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03817398 | Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia | active not recruiting | Phase 2 | 110 | Children's Oncology GroupNETWORK | 4 | Jul 16, 2026 | clinicaltrials |
| NCT03862157 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04062266 | AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04231851 | CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia | active not recruiting | Phase 2 | 30 | University of California, IrvineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05038592 | Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes | active not recruiting | Phase 1 / Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03399773 | Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes | active not recruiting | Phase 2 | 31 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT02935361 | Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed | active not recruiting | Phase 1 / Phase 2 | 33 | University of Southern CaliforniaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT00658814 | Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | active not recruiting | Phase 2 | 133 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02094794 | Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML | active not recruiting | Phase 2 | 108 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03722407 | Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion | active not recruiting | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04802161 | Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT03289910 | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03441113 | Extended Access of Momelotinib in Adults With Myelofibrosis | active not recruiting | Phase 2 | 237 | GlaxoSmithKlineINDUSTRY | 20 | Jun 18, 2026 | clinicaltrials |
| NCT04668885 | CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS | active not recruiting | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03622788 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04517851 | Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03247088 | Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 74 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05364762 | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | active not recruiting | Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT00544115 | Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders | active not recruiting | Phase 2 | 260 | City of Hope Medical CenterOTHER | 0 | Jun 2, 2026 | clinicaltrials |
| NCT04128748 | Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | active not recruiting | Phase 1 / Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03330821 | Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 53 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT02275533 | Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial | active not recruiting | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 2 | May 28, 2026 | clinicaltrials |
| NCT03747757 | Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue | active not recruiting | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04067336 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 263 | Kura Oncology, Inc.INDUSTRY | 7 | May 13, 2026 | clinicaltrials |
| NCT06744556 | HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML | active not recruiting | Phase 2 | 41 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04801797 | Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | active not recruiting | Phase 2 | 172 | Massachusetts General HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05583552 | Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy(IMpress) | active not recruiting | Phase 2 | 46 | GCP-Service International West GmbHINDUSTRY | 3 | May 12, 2026 | clinicaltrials |
| NCT04817007 | A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) | active not recruiting | Phase 1 / Phase 2 | 216 | Bristol-Myers SquibbINDUSTRY | 11 | May 8, 2026 | clinicaltrials |
| NCT05467800 | Study of Canakinumab in Patients With Myelofibrosis | active not recruiting | Phase 2 | 14 | John MascarenhasOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT04872595 | A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant | active not recruiting | Phase 2 | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04217278 | A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT(COSI) | active not recruiting | Phase 2 / Phase 3 | 333 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05732961 | Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms | active not recruiting | Phase 2 | 6 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04493138 | Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations | active not recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04626024 | Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population(TOKIN) | active not recruiting | Phase 2 | 17 | Baylor College of MedicineOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05833438 | Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy(VENAZA-5S) | active not recruiting | Phase 2 | 45 | University of LeipzigOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06497062 | Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 2 | 47 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT01627041 | Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 2 | 178 | National Cancer Institute (NCI)NIH | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03164057 | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 2 | 206 | St. Jude Children's Research HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05428969 | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies(BEXMAB) | active not recruiting | Phase 1 / Phase 2 | 181 | Faron Pharmaceuticals LtdINDUSTRY | 3 | Apr 23, 2026 | clinicaltrials |
| NCT01424982 | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 88 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02250937 | Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | active not recruiting | Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03192397 | Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03431090 | Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia | active not recruiting | Phase 1 / Phase 2 | 20 | Nationwide Children's HospitalOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03610971 | Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors | active not recruiting | Phase 2 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03793478 | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | active not recruiting | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 10 | Apr 1, 2026 | clinicaltrials |
| NCT03286530 | Ruxolitinib + Allogeneic Stem Cell Transplantation in AML | active not recruiting | Phase 2 | 64 | Massachusetts General HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 21, 2026source: clinicaltrials